Control of cell cycle progression in human mesothelioma cells treated with gamma interferon.

Oncogene 2001 Mar 1;20(9):1085-93
Vivo C, Levy F, Pilatte Y, Fleury-Feith J, Chretien P, Monnet I, Kheuang L, Jaurand MC.
INSERM E 99.09, Universite Paris Val de Marne Paris XII (EA 2345), Faculte de Medecine, 8 rue du General Sarrail, 94010, Creteil Cedex, France.

Recombinant human interferon gamma (r-hu-IFNgamma) exerts both antitumoral activity in the early stages of human malignant mesothelioma and a cytostatic effect in human mesothelioma (HM) cell lines in vitro. The antiproliferative effect of interferons (IFNs) reported in a variety of cells has been attributed to several mechanisms. In order to progress in the understanding of HM cell growth modulation by r-hu-IFNgamma, modifications of cell cycle progression and expression of key cell cycle regulator proteins in response to r-hu-IFNgamma were examined. Nine HM cell lines were studied, including one resistant to the antiproliferative effect of r-hu-IFNgamma. Except in the resistant cell line r-hu-IFNgamma produced an arrest in the G1 and G2-M phases of the cell cycle, associated with a reduction in both cyclin A and cyclin dependent kinase inhibitors (CDKIs) expression. Moreover cyclin B1/cdc2 activity was decreased. The present study provides the first evidence of a G2-arrest in r-hu-IFNgamma-treated HM cell lines and indicates that HM cell lines, despite their tumorigenic origin still support cell cycle control. The cell cycle arrest induced by r-hu-IFNgamma seems to depend on cyclin regulation through p21(WAF1/CIP1)- and p27(Kip1)-independent mechanisms and is not directly related to the induced DNA damage.

Source

PMID: 11314045 [PubMed - indexed for MEDLINE]
Click here to order or save article

If you have any questions regarding treatment options or your legal rights, please contact us.

Free Mesothelioma Information Packet

Enter your information to receive a comprehensive mesothelioma packet free of charge at your doorstep within 24 hours.

Yes   No

Mesothelioma Mesothelioma Treatment
Conventional Therapies Alternative Treatments Experimental Therapies Treatment by Stage Mesothelioma Doctors Mesothelioma Experts Clinical Trials Mesothelioma Clinics Ask Your Doctor Caregivers and the Aging Mesothelioma Research Review Studies Case Studies Etiological Studies Diagnostic Studies Therapy Studies Mesothelioma Resources Counseling Resources Mesothelioma Treatment Alerts
Asbestos Cancer Asbestos Exposure Mesothelioma News Veterans & Mesothelioma Mesothelioma Attorney FREE Case Evaluation Top Mesothelioma Doctors

Anne Tsao, M.D.
Dr. Anne Tsao is board certified in medical oncology specializing in thoracic, head, and neck oncology and is director of the Mesothelioma Program at the University of Texas M.D. Anderson Cancer Center.

Claire Verschraegen, M.D.
Dr. Claire Verschraegen is a leading expert in malignant peritoneal mesothelioma and is the Director of the Translational Therapeutics and Phase I Program at the University of New Mexico Cancer Center in Albuquerque.

David Rice, M.D.
Dr. David Rice is an Associate Professor and Assistant Surgeon at The University of Texas M.D. Anderson Cancer Center where he serves as the director of the Minimally Invasive Surgery and Mesothelioma programs.

This website is certified by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here.